Markets
AZN

Health Care Sector Update for 02/05/2015: RXDX, ENTA, AZN

Top Health-care stocks:

JNJ: +0.3%

PFE: +3.5%

ABT: flat

MRK: +0.3%

AMGN: flat

Health-care shares were higher in pre-market trade Thursday.

In health-care stocks news, Ignyta ( RXDX ) reported that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product candidate entrectinib for the treatment of a subset of non-small cell lung cancer.

Shares in the company were unchanged at $6.58 during the pre-market trading session. Over the past 52 weeks, the company has traded between $5.36 and $12.50.

Enanta Pharmaceuticals ( ENTA ) turned a profit in fiscal Q2, helped by a royalty payment from AbbVie related to the regulatory approval of its treatment regimen for genotype 1 HCV patients, but the results missed analysts' expectations.

Shares in the company were unchanged at $36.03 during the pre-market trading session. Over the past 52 weeks, the company has traded between $31.22 and $52.28.

Astrazeneca ( AZN ) was lower in pre-market trade Friday after posting a loss in Q4, while non-GAAP EPS and revenues came in below analyst expectations.

The company reported a quarterly net loss of $321 million, versus last year's $1.5 billion net profit. On a per share basis, this was a loss of $0.25. On a non-GAAP basis, the company reported $0.76 earnings per share, below the $0.83 gain analysts polled by Capital IQ were expecting.

Shares in the company were down $1.6% during the pre-market trading session at $69.90. Over the past 52 weeks, the company has traded between $61.75 and $82.68.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AZN ENTA

Other Topics

Commodities